Treatment for Prostate Cancer

Posts Tagged ‘Prostate’

All November, Bettes and Cantore are growing beards to raise awareness for men’s health issues and prostate cancer awareness. Al Roker, Stephanie Abrams and the participants themselves weigh-in on who has the best beard so far.

Chief of Surgery, Dr. Robert Badalament, discusses the importance for men over 50 to see a urologist at least once a year. Early detection is key in the successful treatment of prostate cancer. The three signs of detection are the PSA blood test, physical examinations, and prostate ultrasound. Patients may delay diagnosis and treatment because they’re afraid to come into urologists, but because many of the treatments are office- and medically-based, they can go home on the same day. Better Care…Better Specialists…A Better Experience The ER at Crittenton – Get Better Here™ www.Crittenton.com

A 55 year-old man, who refused a rectal exam for years, is informed that he has prostate cancer.

Product Description
The genetic and biochemical diversity of marine microorganisms makes them a promising source of useful pharmaceutical agents. The marine cyanobacterium Lyngbya majuscula produces a large number of lipopeptides that are ligands for the voltage-gated sodium channel (VGSC). Compounds that block sodium channel current are known to be effective as anticonvulsants, anesthetics, and anti-arrthymic drugs. In addition, the expression of VGSC’s was found to correlate with the metastatic potential of prostate cancer cells, indicating that sodium channel blockers could have therapeutic use as prostate cancer drugs. The jamaicamides are lipopeptides isolated from L. majuscula that exhibit sodium channel blocking activity at 5 muM. They share a common pharmacophore with the hermitamides, another class of lipopeptides isolated from the same cyanobacterium. The hermitamides are structurally less complex than the jamaicamides but have not been tested for sodium channel activity. Herein, we report the enantioselective synthesis of the hermitamides, their sodium channel activity, and effects on prostate cancer cell proliferation. We also report the enantioselective synthesis of jamaicamide C carboxylic acid. Additional work is reported targeting the dimerization interface of core binding factor (CBF), a protein implicated in the development of acute myelogenous leukemia (AML). A lead compound was designed using computational screening, NMR spectroscopy and x-ray crystallography. A large series of analogues was synthesized and tested for their ability to inhibit dimerization. We have identified several analogues that potently bind to CBF, inhibit dimerization and block proliferation of AML leukemia cell lines.

Synthesis and discovery of lipopeptides from marine sources as sodium channel blockers for the treatment of prostate cancer.

Product Description
Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most-commonly diagnosed and second-leading cause of cancer-related deaths in American men. One of the treatment options being investigated for these patients are active immunotherapies, also known as cancer vaccines, which are designed to harness the patient’s own immune system to recognize and attack tumor cells. However, most antigen-specific vaccines for prostate cancer have yet to demonstrate robust clinical responses, illustrating the importance of identifying new target antigens for vaccine development. One potential antigen is the androgen receptor ligand-binding domain (AR LBD), a steroid hormone receptor that plays a critical role throughout the progression of prostate cancer. While the AR is the primary molecular target for metastatic prostate cancer, we have shown that the AR is also a potential immunological target antigen. We’ve found that some patients with prostate cancer have pre-existing AR LBD-specific immune responses, both in terms of antibody production as well as AR LBD-specific T-cell proliferation. We also identified several AR LBD-derived peptides that have affinity for HLA-A2, shown that prostate cancer patients have T-cells that recognize these peptides, and that some of these T-cells can lyse prostate cancer cells. Utilizing the Topaze transgenic mouse model, we’ve also shown that these HLA-A2-restricted immune responses can be augmented following immunization with a DNA vaccine encoding the AR LBD, and that animals immunized with this vaccine can lyse prostate cancer cells. Furthermore, using the novel Topaze-TRAMP transgenic mouse, we’ve shown that immunization of these mice with an AR LBD DNA vaccine can augment several AR LBD-specific immune responses, as well as a cytotoxic immune response against a syngeneic prostate tumor cell line. Immunization with this vaccine was also found to elicit an anti-tumor response, both in terms of a decrease in adenocarcinoma development as well as an increase in overall survival. These data suggest that the AR LBD is an attractive immunological target for the treatment of prostate cancer, and that a DNA vaccine targeting the AR LBD may be a promising agent for clinical evaluation.

Evaluating the androgen receptor ligand-binding domain as an immunological target for the treatment of prostate cancer.

Product Description
Over the last several decades epidemiological, human migratory studies, pre-clinical and even early phase clinical trials have suggested that dietary constituents may offer a protective effect in reducing the incidence of multiple cancers, including cancer of the prostate. Given the potential that some of these compounds have shown in pre-clinical and even some clinical investigations, it is essential to further identify and develop promising new agents in the hope of creating a broad spectrum of cancer chemopreventive agents. In our studies, we characterized two agents for prostate cancer chemoprevention: carnosol and alpha-mangostin. Carnosol, a dietary diterpene, found in Mediterranean herbs including basil, oregano, sage, and thyme has been shown to decrease prostate cancer cell viability. In our analysis we found carnosol to function as a dual disruptor of the androgen and estrogen receptor-alpha using in vitro and in vivo models. Further study found these traits to be unique when compared to FDA approved anti-androgens and anti-estrogens. alpha-Mangostin, a dietary xanthone, isolated from the mangosteen fruit, was also observed to decrease prostate cancer cell viability. We evaluated alpha-mangostin for kinase inhibition against 50 different kinases. Of those, alpha-mangostin was found to be most effective against CDK4. Our analysis describes the in vitro and in vivo inhibition of prostate cancer using alpha-mangostin. We are proposing that alpha-mangostin and carnosol have unique mechanisms of action and may be further developed as cancer chemopreventive agents.

Selected plant constituents for the prevention and treatment of prostate cancer.

Memorial Sloan-Kettering Cancer Center (MSKCC), the world’s oldest private cancer center, seeks next-generation cancer treatment advances to enhance its ability to treat patients effectively by improving care and reducing costs. Using operations research approaches, our team has devised sophisticated optimization modeling and computational techniques for real-time (intraoperative) treatment of prostate cancer using brachytherapy (the placement of radioactive “seeds” inside a tumor). The resulting system offers significantly safer and more reliable treatment outcomes. In addition, it eliminates the need for preoperative simulation and postimplant dosimetric analysis, resulting in savings of hundreds of millions of dollars per year in the United States alone. Posttreatment quality of life is improved through drastic reduction (up to 45–60 percent) of complications. The reason for this is twofold: (a) treatment plans thus devised deliver less radiation to adjacent healthy structures, and (b) the ability to perform midimplant replanning eliminates the unavoidable discrepancies between planned and actual seed placement in the target. This has a profound impact on the cost of managing treatment-associated morbidity. The procedure uses approximately 20–30 percent fewer seeds and 15 percent fewer needles (used to place seeds inside the prostate gland). As a result, the operating-room time is shortened, and the entire procedure is less invasive. The system has the potential to …

Dr. Rajesh N. Mehra’s interviews with 3 different Urologists in the Washington DC Metro Area regarding treatment of prostate cancer using modern therapy regimens. The urologists are: Dr. Glover, Dr. Bilowus, & Dr. Guleria. These interviews aired on Salaam India, which is a production of Global Television Network. Salaam India airs weekly on MHz Networks and the Executive Producer is Dr. Rajesh N. Mehra, DO of Chantilly Family Practice Center (www.ChantillyMedicalPractice.com). Global TV Network also produces Chitrmala, also seen on MHz Networks. Please see our Youtube channel for more interviews and video clips as well as our website, www.ThisisGTV.com, and also check out Chitrmala’s page on Facebook! This material is copyrighted and is the property of Global Television Networks, Inc. Any unauthorized use or reproduction of this material is strictly prohibited.

Patient testimonial on treatment of Prostate Cancer at the CyberKnife Centers of San Diego, Southern California’s leaders in CyberKnife treatment. Visit us at www.sdcyberknife.com

Product Description

How We Survived Prostate Cancer: What We Did and What We Should Have Done